Chattem FY 1996 second quarter sales advance 12.2% to $30.4 mil..
This article was originally published in The Rose Sheet
Executive Summary
CHATTEM SALES RISE 12.2% TO $30.4 MIL. FOR SECOND QUARTER FY 1996 (ended May 31), the company announced June 20. U.S. sales were ahead 4%, spurred by the additions of the Gold Bond medicated powder and cream brands and the May 1 launch of pHisoDerm antibacterial skin cleanser ("The Rose Sheet" Feb. 5, p. 7), the company said
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.